Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01755325
Recruitment Status : Suspended (not enough patients)
First Posted : December 24, 2012
Last Update Posted : April 25, 2018
Information provided by (Responsible Party):
Junmin Li, Ruijin Hospital

No Study Results Posted on for this Study
  Recruitment Status : Suspended
  Estimated Primary Completion Date : December 2018
  Estimated Study Completion Date : December 2018